Cardiomyopathy: Difference between revisions

Jump to navigation Jump to search
Line 32: Line 32:




==Microscopic Pathological Findings==
[http://www.peir.net Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
<div align="left">
<gallery heights="175" widths="175">
Image:438.jpg|Cardiomyopathy: Micro H&E high mag excellent example myofiber disarray
Image:439.jpg|Cardiomyopathy: Micro H&E low mag interventricular septum at junction of normal myofiber orientation with asymmetrical hypertrophy (an excellent example)
</gallery>
</div>
<div align="left">
<gallery heights="175" widths="175">
Image:432.jpg|Cardiomyopathy: Micro trichrome low mag bizarre vacuolated fibers with disarray and focal fibrosis excellent low mag epicardial surface
Image:666.jpg|Alcoholic Cardiomyopathy: Micro plastic section lipid in perinuclear area loss of myofibrils
</gallery>
</div>


== References ==
== References ==

Revision as of 17:13, 16 October 2011

For patient information click here

Cardiomyopathy
Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium {Autopsy findings}.
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology
ICD-10 I42.0
ICD-9 425.4
DiseasesDB 2137
MeSH D009202

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy

CDC on Cardiomyopathy

Cardiomyopathy in the news

Blogs on Cardiomyopathy

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Cardiomyopathy, which literally means "heart muscle disease", is the deterioration of the function of the myocardium (i.e., the actual heart muscle) for any reason. People with cardiomyopathy are often at risk of arrhythmia or sudden cardiac death or both.[1]

Cardiomyopathies can generally be categorized into two groups, based on World Health Organization guidelines: extrinsic cardiomyopathies and intrinsic cardiomyopathies.[2]

In general definition;

Cardiomyopathies are myocardial diseases that independent of:


References

  1. Kasper, Denis L.; et al. (2005). Harrison's Principles of Internal Medicine, 16th edn. McGraw-Hill. ISBN 0-07-139140-1.
  2. Richardson, P.; et al. (1996). "Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies". Circulation. 93 (5): 841–2. PMID 8598070. (Full text)

External links

de:Kardiomyopathie nl:Cardiomyopathie no:Kardiomyopati simple:Cardiomyopathy sr:Кардиомиопатија sv:Hjärtmuskelsjukdom


Template:WikiDoc Sources